SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
EPS Growth Recovery in ProgressRecovering
Percentile Rank83
5Y CAGR-45.5%
Studio
Year-over-Year Change

Year-over-year earnings per share growth rate

5Y CAGR
-45.5%/yr
Long-term compound
Percentile
P83
Within normal range
vs 5Y Ago
0x
Contraction
Streak
2 yr
Consecutive growthRecovering
PeriodValue
2025105.98%
202451.83%
2023-77.26%
2022-9.39%
2021-185.10%
20202204.55%
20190.00%